Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Interferon alpha-2a
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
Interferon alpha-2a (Azidus Brasil) is a recombinant Type I interferon developed by Blausiegel (with clinical trials managed by Azidus Brasil) as a biosimilar version of Roche's Roferon A. It is a cytokine that binds to the interferon-alpha/beta receptor (IFNAR) complex, initiating a signaling cascade via the JAK-STAT pathway. This results in the induction of various interferon-stimulated genes that exert antiviral, antiproliferative, and immunomodulatory effects. In the context of Hepatitis C, it inhibits viral replication and enhances the host immune response against the hepatitis C virus (HCV). The drug was evaluated in pharmacokinetic and pharmacodynamic studies in Brazil to demonstrate bioequivalence to the reference product, Roferon A.
- Brand names
- Roferon-A
- Other names
- alpha interferon-2AIFN-alpha 2aIFN-alpha2aIFN-alpha-2aInterferon alfa-2a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on Interferon alpha-2a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interferon alpha-2a.